Natsuko Chiba

Sendai, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B).

BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B).

Journal: Breast cancer (Tokyo, Japan)

Published: February 24, 2026

BET family BRD3 initiates DSB-induced chromatin remodeling with TIP60 to promote R-loop-mediated HR.

BET family BRD3 initiates DSB-induced chromatin remodeling with TIP60 to promote R-loop-mediated HR.

Journal: Cell reports

Published: March 18, 2025

Assay for Site-Specific Homologous Recombination Activity in Adherent Cells, Suspension Cells, and Tumor Tissues.

Assay for Site-Specific Homologous Recombination Activity in Adherent Cells, Suspension Cells, and Tumor Tissues.

Journal: Bio-protocol

Published: December 04, 2024

Nicaraven enhances the cytotoxicity of X-ray irradiation in cancer cells with homologous recombination deficiency.

Nicaraven enhances the cytotoxicity of X-ray irradiation in cancer cells with homologous recombination deficiency.

Journal: Biochemical and biophysical research communications

Published: November 30, 2024

The centrosome: a critical hub for cell cycle regulation.

The centrosome: a critical hub for cell cycle regulation.

Journal: Trends in cell biology

Published: April 15, 2024

Protocol to detect OLA1 polyubiquitination by Aurora A in vivo and in vitro.

Protocol to detect OLA1 polyubiquitination by Aurora A in vivo and in vitro.

Journal: STAR protocols

Published: January 22, 2024

Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity.

Evaluating homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and olaparib sensitivity.

Journal: Scientific reports

Published: October 25, 2023

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway.

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway.

Journal: Frontiers in oncology

Published: September 27, 2023

Knockout of Brca1-interacting factor Ola1 in female mice induces tumors with estrogen suppressible centrosome amplification.

Knockout of Brca1-interacting factor Ola1 in female mice induces tumors with estrogen suppressible centrosome amplification.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: September 19, 2023

Aurora A polyubiquitinates the BRCA1-interacting protein OLA1 to promote centrosome maturation.

Aurora A polyubiquitinates the BRCA1-interacting protein OLA1 to promote centrosome maturation.

Journal: Cell reports

Published: January 20, 2023

Functional evaluation of BRCA1/2 variants of unknown significance with homologous recombination assay and integrative in silico prediction model.

Functional evaluation of BRCA1/2 variants of unknown significance with homologous recombination assay and integrative in silico prediction model.

Journal: Journal of human genetics

Published: December 25, 2022

Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.

Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.

Journal: Journal of gastrointestinal oncology

Published: September 09, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026